Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients-Reference-Cited by-同舟云学术

Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients

Published:2012-12-17 Issue:1 Volume:18 Page:63-70
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Chadban Steve¹,Eris Josette¹,Russ Graeme²,Campbell Scott³,Chapman Jeremy⁴,Pussell Bruce⁵,Trevillian Paul⁶,Ierino Francesco⁷,Thomson Napier⁸,Hutchison Brian⁹,Irish Ashley¹⁰,Woodcock Chad¹¹,Kurstjens Nicol¹¹,Walker Rowan¹²,

Affiliation:

1. Transplantation; Royal Prince Alfred Hospital; Sydney; Australia

2. Department of Nephrology and Transplantation; Royal Adelaide Hospital; Adelaide; South Australia; Australia

3. Renal Medicine; Princess Alexandria Hospital; Brisbane; Queensland; Australia

4. Westmead Millenium Institute; Centre for Transplant and Renal Research; Westmead Hospital; Sydney; Australia

5. Department of Nephrology; Prince of Wales Hospital; Sydney; Australia

6. Transplantation Unit; John Hunter Hospital; Newcastle; New South Wales; Australia

7. Department of Nephrology; Austin Health; Melbourne; Australia

8. The Alfred Hospital and Monash University; Melbourne; Australia

9. Renal Medicine; Sir Charles Gardiner Hospital; Perth; Western Australia; Australia

10. Department of Nephrology; Royal Perth Hospital; Perth; Western Australia; Australia

11. Novartis Pharmaceuticals Australia; Sydney; Australia

12. Department of Nephrology; Royal Melbourne Hospital; Melbourne; Australia

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nep.12004/fullpdf

Reference23 articles.

1. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers;Rupprecht;J. Clin. Pharmacol.,2009

2. The natural history of chronic allograft nephropathy;Nankivell;N. Engl. J. Med.,2003

3. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomised, double blind, clinical studies in prevention of rejection;Halloran;Transplantation,1997

4. Placebo-controlled study of Mycophenolate Mofetil combined with Cyclosporine and Corticosteroids for prevention of acute rejection;European Mycophenolate Mofetil Cooperation Study Group;Lancet,1995

5. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil;Hardinger;Transpl. Int.,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients;Cochrane Database of Systematic Reviews;2017-07-21

2. Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium inDe NovoKidney Transplantation;Yonsei Medical Journal;2017

3. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation;Health Technology Assessment;2016-08

4. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis;American Journal of Transplantation;2016-03-15

5. Enteric-coated mycophenolate sodium: an update;International Journal of Clinical Practice;2014-03-27